167 related articles for article (PubMed ID: 38215984)
21. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
[TBL] [Abstract][Full Text] [Related]
22. Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin.
Mendonça MCP; Sun Y; Cronin MF; Lindsay AJ; Cryan JF; O'Driscoll CM
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839842
[TBL] [Abstract][Full Text] [Related]
23. Sexual behavior and testis morphology in the BACHD rat model.
Novati A; Yu-Taeger L; Gonzalez Menendez I; Quintanilla Martinez L; Nguyen HP
PLoS One; 2018; 13(6):e0198338. PubMed ID: 29883458
[TBL] [Abstract][Full Text] [Related]
24. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.
Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR
Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117
[TBL] [Abstract][Full Text] [Related]
25. Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels.
Bailus BJ; Scheeler SM; Simons J; Sanchez MA; Tshilenge KT; Creus-Muncunill J; Naphade S; Lopez-Ramirez A; Zhang N; Lakshika Madushani K; Moroz S; Loureiro A; Schreiber KH; Hausch F; Kennedy BK; Ehrlich ME; Ellerby LM
Autophagy; 2021 Dec; 17(12):4119-4140. PubMed ID: 34024231
[TBL] [Abstract][Full Text] [Related]
26. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
27. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
28. A pathogenic proteolysis-resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function.
Kim H; Lenoir S; Helfricht A; Jung T; Karneva ZK; Lee Y; Beumer W; van der Horst GB; Anthonijsz H; Buil LC; van der Ham F; Platenburg GJ; Purhonen P; Hebert H; Humbert S; Saudou F; Klein P; Song JJ
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35943803
[TBL] [Abstract][Full Text] [Related]
29. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
30. Small molecule splicing modifiers with systemic HTT-lowering activity.
Bhattacharyya A; Trotta CR; Narasimhan J; Wiedinger KJ; Li W; Effenberger KA; Woll MG; Jani MB; Risher N; Yeh S; Cheng Y; Sydorenko N; Moon YC; Karp GM; Weetall M; Dakka A; Gabbeta V; Naryshkin NA; Graci JD; Tripodi T; Southwell A; Hayden M; Colacino JM; Peltz SW
Nat Commun; 2021 Dec; 12(1):7299. PubMed ID: 34911927
[TBL] [Abstract][Full Text] [Related]
31. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.
Southwell AL; Skotte NH; Villanueva EB; Østergaard ME; Gu X; Kordasiewicz HB; Kay C; Cheung D; Xie Y; Waltl S; Dal Cengio L; Findlay-Black H; Doty CN; Petoukhov E; Iworima D; Slama R; Ooi J; Pouladi MA; Yang XW; Swayze EE; Seth PP; Hayden MR
Hum Mol Genet; 2017 Mar; 26(6):1115-1132. PubMed ID: 28104789
[TBL] [Abstract][Full Text] [Related]
32. Oligonucleotide therapeutic approaches for Huntington disease.
Sah DW; Aronin N
J Clin Invest; 2011 Feb; 121(2):500-7. PubMed ID: 21285523
[TBL] [Abstract][Full Text] [Related]
33. Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression.
Bahat A; Itzhaki E; Weiss B; Tolmasov M; Tsoory M; Kuperman Y; Brandis A; Shurrush KA; Dikstein R
EMBO Mol Med; 2024 Mar; 16(3):523-546. PubMed ID: 38374466
[TBL] [Abstract][Full Text] [Related]
34. In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using
Bertoglio D; Weiss AR; Liguore W; Martin LD; Hobbs T; Templon J; Srinivasan S; Dominguez C; Munoz-Sanjuan I; Khetarpal V; Verhaeghe J; Staelens S; Link J; Liu L; Bard JA; McBride JL
J Nucl Med; 2023 Oct; 64(10):1581-1587. PubMed ID: 37591545
[TBL] [Abstract][Full Text] [Related]
35. Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting.
Caron NS; Anderson C; Black HF; Sanders SS; Lemarié FL; Doty CN; Hayden MR
J Huntingtons Dis; 2021; 10(3):355-365. PubMed ID: 34092649
[TBL] [Abstract][Full Text] [Related]
36. Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation.
Pierzynowska K; Podlacha M; Gaffke L; Rintz E; Wiśniewska K; Cyske Z; Węgrzyn G
Autophagy; 2024 May; 20(5):1159-1182. PubMed ID: 37992314
[TBL] [Abstract][Full Text] [Related]
37. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
[TBL] [Abstract][Full Text] [Related]
38. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
[TBL] [Abstract][Full Text] [Related]
39. Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease.
Jiang M; Zhang X; Liu H; LeBron J; Alexandris A; Peng Q; Gu H; Yang F; Li Y; Wang R; Hou Z; Arbez N; Ren Q; Dong JL; Whela E; Wang R; Ratovitski T; Troncoso JC; Mori S; Ross CA; Lim J; Duan W
Hum Mol Genet; 2020 May; 29(8):1340-1352. PubMed ID: 32242231
[TBL] [Abstract][Full Text] [Related]
40. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
